169 related articles for article (PubMed ID: 18325065)
1. Bortezomib-induced reversible posterior leucoencephalopathy syndrome.
Kelly K; Kalachand R; Murphy P
Br J Haematol; 2008 May; 141(5):566. PubMed ID: 18325065
[No Abstract] [Full Text] [Related]
2. Reversible posterior encephalopathy syndrome associated with bortezomib.
Terwiel E; Hanrahan R; Lueck C; D'Rozario J
Intern Med J; 2010 Jan; 40(1):69-71. PubMed ID: 20561367
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib-induced posterior reversible encephalopathy syndrome: clinical and imaging features.
Ho CH; Lo CP; Tu MC
Intern Med; 2014; 53(16):1853-7. PubMed ID: 25130124
[TBL] [Abstract][Full Text] [Related]
4. Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin.
Pinedo DM; Shah-Khan F; Shah PC
J Clin Oncol; 2007 Nov; 25(33):5320-1. PubMed ID: 18024878
[No Abstract] [Full Text] [Related]
5. Posterior reversible encephalopathy syndrome resulting from repeat bortezomib usage.
Nixon NA; Parhar K
BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24903728
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib-induced Sweet syndrome.
Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
[No Abstract] [Full Text] [Related]
7. Bortezomib-induced lupus erythematosus tumidus.
Böckle BC; Baltaci M; Weyrer W; Sepp NT
Oncologist; 2009 Jun; 14(6):637-9. PubMed ID: 19474161
[No Abstract] [Full Text] [Related]
8. Persistent supravenous eruption induced by intravenous bortezomib therapy.
Mataix J; Betlloch I; Palmero F; Romero A
Br J Dermatol; 2008 Apr; 158(4):863-4. PubMed ID: 18284402
[No Abstract] [Full Text] [Related]
9. Bortezomib-induced posterior reversible encephalopathy syndrome in a patient with newly diagnosed multiple myeloma.
Oshikawa G; Kojima A; Doki N; Kobayashi T; Kakihana K; Tsuda H; Endo I; Kamata N; Ohashi K; Sakamaki H
Intern Med; 2013; 52(1):111-4. PubMed ID: 23291684
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-induced acute pancreatitis.
Elouni B; Ben Salem C; Zamy M; Sakhri J; Bouraoui K; Biour M
JOP; 2010 May; 11(3):275-6. PubMed ID: 20442528
[No Abstract] [Full Text] [Related]
11. Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
Hattori N; Adachi D; Nakashima H; Saito B; Nakamaki T; Tomoyasu S
Leuk Res; 2009 Apr; 33(4):574-7. PubMed ID: 18838167
[No Abstract] [Full Text] [Related]
12. Bortezomib-associated cutaneous vasculitis.
Garcia-Navarro X; Puig L; Fernández-Figueras MT; Dalmau J; Roe E; Alomar A
Br J Dermatol; 2007 Oct; 157(4):799-801. PubMed ID: 17635511
[No Abstract] [Full Text] [Related]
13. Bortezomib-induced skin eruption.
Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
[TBL] [Abstract][Full Text] [Related]
14. Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance.
Foley PW; Hamilton MS; Leyva F
J Cardiovasc Med (Hagerstown); 2010 May; 11(5):386-8. PubMed ID: 19584744
[TBL] [Abstract][Full Text] [Related]
15. [Bortezomib-induced acute neutrophilic dermatosis].
Tanguy-Schmidt A; Avenel-Audran M; Croué A; Lissandre S; Dib M; Zidane-Marinnes M; Moles MP; Hunault-Berger M
Ann Dermatol Venereol; 2009 May; 136(5):443-6. PubMed ID: 19442803
[TBL] [Abstract][Full Text] [Related]
16. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.
Fang B; Song Y; Ma J; Zhao RC
Acta Haematol; 2007; 118(2):65-7. PubMed ID: 17505132
[No Abstract] [Full Text] [Related]
17. Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain.
Mangiacavalli S; Corso A; De Amici M; Varettoni M; Alfonsi E; Lozza A; Lazzarino M
Br J Haematol; 2010 Jun; 149(6):916-8. PubMed ID: 20201942
[No Abstract] [Full Text] [Related]
18. [Reversible posterior leukoencephalopathy: the guilty list is increasing].
Alaña M; Navarro M; Pascual J
Neurologia; 2008 Mar; 23(2):137; author reply 137-8. PubMed ID: 18322836
[No Abstract] [Full Text] [Related]
19. Deafness associated with the use of Bortezomib in multiple myeloma.
Chim CS; Wong LG
Acta Oncol; 2008; 47(2):323-4. PubMed ID: 17851876
[No Abstract] [Full Text] [Related]
20. Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib.
Yokose N; Hirakawa T; Inokuchi K
Leuk Res; 2009 Aug; 33(8):e106. PubMed ID: 19285724
[No Abstract] [Full Text] [Related]
[Next] [New Search]
